<DOC>
	<DOCNO>NCT02242812</DOCNO>
	<brief_summary>The primary objective show telmisartan inferior metoprolol succinate respect percentage change baseline LVMI ( H ) 6.5 month treatment period . As secondary objective , improvement leave ventricular systolic diastolic function blood pressure reduction assess</brief_summary>
	<brief_title>Telmisartan Effectiveness Left Ventricular Mass Reduction ( TELMAR ) Assessed MRI , Patients With Mild Moderate Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Caucasian nonCaucasian patient i.e . Asian patient untreated essential hypertension define either mean systolic blood pressure ( SBP ) &gt; = 140 mm Hg mean diastolic blood pressure ( DBP ) &gt; = 90 mm Hg normal daily activity ( 6:00 21:59 h ) and/or nocturnal ( 22:00 05:59 h ) SBP mean &gt; = 120 mm Hg DBP mean &gt; = 70 mm Hg measure ABPM . Presence Left Ventricular Hypertrophy ( LVH ) define MRI : Caucasian patient : Left ventricular mass &gt; 0.8 g/cm woman &gt; 1.05 g/cm men . NonCaucasian i.e . Asian patient : Left ventricular mass &gt; 0.65 g/cm woman &gt; 0.85 g/cm men Age 18 80 year Written inform consent accordance Good Clinical Practice ( GCP ) guideline local regulatory legal requirement Contraindications class drug study : Contraindications β Blocker angiotensin receptor antagonists A history angioedema know hypersensitivity component formulation Contraindications ethical ground : specific contraindication ethical ground foreseen study General Contraindications : Pregnancy , lactation child bear potential ( I.e . Premenopausal woman ( last menstruation &lt; 1 year prior start runin phase ) surgically sterile ( hysterectomy , tubal ligation ) NOR practice NOT plan practice acceptable mean birth control ( Intrauterine Device , oral implantable injectable contraceptive ) positive serum pregnancy test screen baseline ) Factors make follow difficult ( i.e . fixed address ) Treatment investigational drug within one month signing informed consent Clinically significant concomitant disease : Hepatic and/or renal dysfunction define follow laboratory parameter : 1 . Alanine amino transferase ( SGPT ( ALT ) ) Aspartate amino transferase ( SGOT ( AST ) ) value two time Gamma glutaryl transferase ( GammaGT ) three time upper normal limit 2 . Serum creatinine &gt; 150 mol/L Clinically significant sodium potassium depletion , clinically relevant hyperkalaemia Uncorrected volume depletion Primary aldosteronism Hereditary fructose intolerance Biliary obstructive disorder , cholestasis moderate severe hepatic insufficiency Insulindependent diabetes mellitus Congestive heart failure ejection fraction &lt; 35 % New York Heart Association ( NYHA ) class III IV Unstable Angina Sustained ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine investigator Postrenal transplant patient Myocardial infarction cardiac surgery within precede six month Known drug alcohol abuse within 6 month prior start study Patients MRI contraindication : Implanted pacemaker defibrillator Implanted vascular clip Gross obesity ( i.e . patient weight &gt; 150 kg ) Specific exclusion disease study : Known suspect secondary hypertension Known renal artery stenosis Known endocrine disorder secondary hypertension Severe arterial hypertension define mean seated DBP &gt; 115 mmHg mean seat SBP &gt; 200 mmHg Patients complete loss diurnal BP variation , define lack drop BP sleeping time drop le 5 % compare daily mean BP Hypertrophic obstructive cardiomyopathy , clinically relevant aortic valve stenosis clinically relevant mitral valve disease ; vascular disease affect BP ( coarctation ; stenosis A. subclavia ) Specific concomitant therapy exclusion : Use antihypertensive medication within previous six month Chronic administration digoxin digitalistype drug , without regular monitoring plasma level Chronic administration medication know affect blood pressure , except medication allow protocol Continuous ( two week ) treatment within last three month use least follow drug : β blocker , angiotensin convert enzyme inhibitor , angiotensin receptor blocker Participation another drug trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>